Trevi Therapeutics
TRVI
18 hedge funds and large institutions have $106M invested in Trevi Therapeutics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
79.44% more ownership
Funds ownership: 0% → 79.44% (+79%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$54.5M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$38.1M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$10.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.83M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$6.03M |
Top Sellers
TRVI Hedge Fund Activity: Q2 2019 in Review
18 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2019, worth a combined $106M.
Buyers outnumbered sellers: 18 funds opened new TRVI positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $54.5M.
- 18 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $106M of Trevi Therapeutics stock for Q2 2019.
- 18 funds opened new Trevi Therapeutics positions in Q2 2019 and 0 closed out, a net change of +18 holders.
- The largest Trevi Therapeutics buyer in Q2 2019 was TPG Group Holdings (SBS) Advisors, an estimated $54.5M added.
Based on aggregated 13F filings for Q2 2019.